title: New therapies for chronic hepatitis B.
abstract: Currently, the only therapy of proven benefit in chronic hepatitis B is interferon-alpha which leads to a long-term benefit in only one-third of patients. New therapies for hepatitis B fall into three categories; antiviral chemotherapy, immunomodulation with cell-based therapies, vaccines or cytokines, and gene therapy such as with antisense oligonucleotides, ribozymes or viral mutants. The most promising immediate approach to therapy is with the new nucleoside antivirals--lamivudine and famciclovir. These drugs are well absorbed orally, result in profound inhibition of circulating hepatitis B virus, and, in some cases, loss of hepatitis B e antigen and improvement in serum aminotransferases. Controlled trials of long-term famciclovir and lamivudine therapy currently underway aim to show whether these drugs are safe and can provide sustained inhibition of viral replication and attentant improvement in liver disease.
authors.affiliation: Liver Diseases Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda 20892, USA.
authors.forename: J H
authors.initials: JH
authors.lastname: Hoofnagle
authors.forename: D
authors.initials: D
authors.lastname: Lau
mesh_terms: D000818:Animals; D002908:Chronic Disease; D015316:Genetic Therapy; D006509:Hepatitis B / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy